BioSpace News Archive

IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share.

Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the commercial launch of the Adductoplasty™ System.

Hyperfine Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop™, will host a virtual Analyst and Investor Meeting on Monday, September 27, 2021 from 10:00 a.m. to approximately 12:00 p.m. Eastern Time.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (“IND”) to undertake a clinical study of the Company’s investigational kidney cancer therapy, TLX250 (177Lu-DOTA-girentuximab).

Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) (NYSE: JNJ) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years.

Telix Pharmaceuticals Limited has welcomed the updated National Comprehensive Cancer Network® Guidelines® for prostate cancer,1 which includes prostate specific membrane antigen positron emission tomography imaging modalities, including Ga-68 PSMA-11.

Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC) without driver mutations.

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Nasdaq: CHRS) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411).